CM-4307

Generic Name: CM-4307

Drug Type: Small Molecule

Chemical Formula: C_₂₁H_₁₆ClF_₃N_₄O_₃

CAS Number: 1130115-44-4

Unique Ingredient Identifier: 41XGO0VS1U

Background: CM-4307 is under investigation in clinical trial NCT03602495 (Donafenib in 131I-Refractory Differentiated Thyroid Cancer).

Indication: 用于治疗既往未接受过全身系统性治疗的不可手术切除或转移性肝细胞癌患者。

Clinical Trials

A Study of Donafenib Plus S-1 in Treating Patients With Metastatic Pancreatic Cancer After Chemotherapy With Nab-paclitaxel Plus Gemcitabine Regimen

Phase 2

Conditions: Metastatic Pancreatic Cancer

Interventions: Drug: Donafenib
Drug: S1

First Posted Date: 2021-11-30

Last Posted Date: 2021-11-30

Lead Sponsor: Fudan University

Target Recruit Count: 10

Registration Number: NCT05138159

Locations: 🇨🇳
Fudan University, Shanghai, China

Clinical Study of Radiotherapy Combined With Donafenib for Neoadjuvant Treatment of Patients With HCC With Portal Vein Carcinoma Thrombosis

Phase 4

Conditions: HCC
Chemotherapy Effect

Interventions: Drug: Donafenib

First Posted Date: 2021-08-26

Last Posted Date: 2021-09-21

Lead Sponsor: Anhui Provincial Hospital

Target Recruit Count: 30

Registration Number: NCT05022628

Hepatic Artery Infusion Chemotherapy Plus Donafenib in Patients With Hepatocellular Carcinoma After Surgery

Phase 2

Not yet recruiting

Conditions: Donafenib
Oxaliplatin
Carcinoma
Carcinoma, Hepatocellular
Liver Neoplasms
Digestive System Neoplasms
Fluorouracil
Antimetabolites
Antineoplastic Agents

Interventions: Procedure: Hepatic arterial infusion chemotherapy
Drug: Folfox Protocol
Drug: Donafenib

First Posted Date: 2021-07-15

Last Posted Date: 2023-06-22

Lead Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Target Recruit Count: 30

Registration Number: NCT04962958

Locations: 🇨🇳
Lei Zhang, Guangzhou, Guangdong, China

A Phase 1/2 Study of Donafenib in Combination With KN046 in Advanced Gastrointestinal Tumors

Phase 1

Recruiting

Conditions: Advanced Gastrointestinal Tumors

Interventions: Drug: Donafenib Tosilate Tablets
Biological: KN046 Injection

First Posted Date: 2020-11-03

Last Posted Date: 2022-11-29

Lead Sponsor: Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Target Recruit Count: 42

Registration Number: NCT04612712

Locations: 🇨🇳
Zhongshan Hospital Affiliated to Fudan University, Shanghai, China

Donafenib and Toripalimab Combined With TACE in Patients With Unresectable Hepatocellular Carcinoma

Phase 1

Active, not recruiting

Conditions: Unresectable Hepatocellular Carcinoma

Interventions: Drug: Donafenib Tosilate Tablets
Biological: Toripalimab Injection

First Posted Date: 2020-10-27

Last Posted Date: 2024-03-06

Lead Sponsor: Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Target Recruit Count: 18

Registration Number: NCT04605185

Locations: 🇨🇳
Hunan Cancer Hospital, Changsha, Hunan, China

Toripalimab Combined With Donafenib in the Treatment of Advanced Hepatocellular Carcinoma

Phase 1

Recruiting

Conditions: Advanced Hepatocellular Carcinoma

Interventions: Drug: Donafenib Tosilate Tablets
Drug: Toripalimab Injection

First Posted Date: 2020-08-07

Last Posted Date: 2022-11-29

Lead Sponsor: Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Target Recruit Count: 46

Registration Number: NCT04503902

Locations: 🇨🇳
No.81 Hospital of PLA, Nanjing, Jiangsu, China

A Study of CS1001 in Combination With Donafenib in Subjects With Advanced Solid Tumors

Phase 1

Recruiting

Conditions: Advanced Solid Tumor

Interventions: Drug: Donafenib
Drug: CS1001

First Posted Date: 2020-07-16

Last Posted Date: 2022-11-29

Lead Sponsor: Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Target Recruit Count: 30

Registration Number: NCT04472858

Locations: 🇨🇳
Shanghai Eastern Hospital, Shanghai, Shanghai, China

Study on the Safety and Efficacy of Donafinib Combined With Anti-PD-1 Antibody as Adjuvant Therapy for HCC Patients

Phase 1

Recruiting

Conditions: Hepatocellular Carcinoma

Interventions: Drug: Donafenib and anti-PD-1 antibody

First Posted Date: 2020-06-05

Last Posted Date: 2023-06-13

Lead Sponsor: Zhejiang University

Target Recruit Count: 30

Registration Number: NCT04418401

Locations: 🇨🇳
the First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China

Combination of Donafenib and Cytarabine/Daunorubicin in Relapsed AML

Phase 1

Terminated

Conditions: Acute Myeloid Leukemia (AML)

Interventions: Drug: Donafenib

First Posted Date: 2020-05-27

Last Posted Date: 2022-12-01

Lead Sponsor: Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Target Recruit Count: 8

Registration Number: NCT04402723

Locations: 🇨🇳
Institute of Hematology and Blood Disease Hospital, Tianjin, Tianjin, China

Treatment of Non-small Cell Lung Cancer With PD-1 Monoclonal Antibody Combined With Donafenib Toluene Sulfonate

Phase 1

Conditions: Non-small Cell Lung Cancer

Interventions: Drug: donafenib tablets

First Posted Date: 2019-08-16

Last Posted Date: 2019-08-16

Lead Sponsor: First Affiliated Hospital of Zhejiang University

Target Recruit Count: 20

Registration Number: NCT04059874

Locations: 🇨🇳
The First Affiliated Hospital of College of Medicine Zhejiang University, Hangzhou, Zhejiang, China

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy